Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Nature communications - 8 Feb 2021

Samur Mehmet Kemal, Fulciniti Mariateresa, Aktas Samur Anil, Bazarbachi Abdul Hamid, Tai Yu-Tzu, Prabhala Rao, Alonso Alejandro, Sperling Adam S, Campbell Timothy, Petrocca Fabio, Hege Kristen, Kaiser Shari, Loiseau Hervé Avet, Anderson Kenneth C, Munshi Nikhil C

Abstract excerpt

BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal samples from a patient who relapsed after initial CAR T cell treatment with lack of response to retreatment. We report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CAR-T cell therapy research

Share to Drug Resistance, Neoplasm

Share to Immunotherapy, Adoptive

Share to Monoclonal and Polyclonal Antibodies Research

Share to Multiple Myeloma

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33558511
DOI: 10.1038/s41467-021-21177-5
PMCID: PMC7870932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.PMID 33558511Read ↗

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myelomaSemantic proximity Read ↗

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read ↗

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.Semantic proximity Read ↗

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myelomaSemantic proximity Read ↗

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.Semantic proximity Read ↗

Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.Semantic proximity Read ↗

Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression.Semantic proximity Read ↗

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaSemantic proximity Read ↗

Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple MyelomaSemantic proximity Read ↗

Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaSemantic proximity Read ↗

Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesSemantic proximity Read ↗

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.